Abraxane Survey 2017

In September 2015 the National Institute for Health and Care Excellence (NICE) decided not to recommend a new pancreatic cancer drug, Abraxane, for use on the NHS in England and, by extension, Northern Ireland. Initially NICE said they would not look at Abraxane again until October 2018. However, new evidence has been provided to them and they have now brought forward the reappraisal. 

Pancreatic Cancer UK has been asked to respond to NICE by 17th March, giving our opinion as to whether and why the drug should be made available to patients on the NHS. To help us do so, we would welcome the input of patients and the family and friends of patients who have/had advanced pancreatic cancer. We would especially welcome input from patients, or the family and friends of patients who have been treated with Abraxane, and the views of patients in Wales and Scotland who currently have access to the drug.

All answers to the survey are anonymous. However, you can provide your contact details so we can contact you to discuss your answers in more depth if we need to. We fully abide by our Privacy Policy, which is available to view on our website.

If you have any questions, please feel free to email campaigning@pancreaticcancer.org.uk.

Thank you very much for taking the time to help us by sharing your experiences in this way. By doing so, you are helping us to put forward the most informed case possible to NICE.